S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

$236.54
-11.99 (-4.82%)
(As of 02/23/2024 ET)
Today's Range
$235.08
$249.98
50-Day Range
$171.37
$248.53
52-Week Range
$119.76
$322.67
Volume
469,225 shs
Average Volume
489,710 shs
Market Capitalization
$4.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$304.00

Madrigal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
28.5% Upside
$304.00 Price Target
Short Interest
Healthy
19.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.80mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Acquiring Shares
$17.81 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($19.46) to ($15.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.79 out of 5 stars

Medical Sector

41st out of 939 stocks

Pharmaceutical Preparations Industry

15th out of 439 stocks


MDGL stock logo

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Stock Price History

MDGL Stock News Headlines

Analysts see over 50% gains in these 2 mid-cap biotech stocks
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way drugs are developed and health care is administered. Advancements in the treatment of cancer, Alzheimer's disease and obesity have highlighted steady progress in the field.
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Up 7.7%
MDGL Mar 2024 185.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MDGL Mar 2024 340.000 call
MDGL Mar 2024 110.000 put
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
92
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$304.00
High Stock Price Target
$347.00
Low Stock Price Target
$224.00
Potential Upside/Downside
+28.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-295,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.54 per share

Miscellaneous

Free Float
15,020,000
Market Cap
$4.68 billion
Optionable
Optionable
Beta
-0.48

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Rebecca A. Taub M.D. (Age 72)
    Founder, Chief Medical Officer, President of Research & Development and Director
    Comp: $939.83k
  • Mr. Alex G. Howarth (Age 55)
    Senior VP & CFO
    Comp: $757.26k
  • Mr. Brian J. Lynch J.D. (Age 62)
    Senior VP & General Counsel
    Comp: $763.75k
  • Mr. William J. Sibold (Age 58)
    CEO, President & Director
  • Mr. Ronald Filippo
    Chief Information Officer
  • Ms. Tina E. Ventura
    Chief Investor Relations Officer
  • Dr. Kianoush Motesharei Ph.d. (Age 54)
    Senior Vice President of Business & Corporate Development
  • Mr. Clint Wallace
    Chief Human Resources Officer
  • Mr. Edward Chiang
    Senior Vice President of Clinical & Technical Operations
  • Mr. Thomas W. Hare
    Senior Vice President of Clinical Management














MDGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price objectives for Madrigal Pharmaceuticals' stock. Their MDGL share price targets range from $224.00 to $347.00. On average, they anticipate the company's stock price to reach $304.00 in the next year. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2024?

Madrigal Pharmaceuticals' stock was trading at $231.38 on January 1st, 2024. Since then, MDGL stock has increased by 2.2% and is now trading at $236.54.
View the best growth stocks for 2024 here
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings data on Monday, November, 6th. The biopharmaceutical company reported ($5.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.90) by $0.44.

What ETFs hold Madrigal Pharmaceuticals' stock?
What other stocks do shareholders of Madrigal Pharmaceuticals own?
Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.57%), Vanguard Group Inc. (7.98%), Paulson & CO. Inc. (5.60%), RTW Investments LP (4.13%), Price T Rowe Associates Inc. MD (1.97%) and Price T Rowe Associates Inc. MD (1.97%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, Remy Sukhija, Richard S Levy and Robert E Waltermire.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDGL) was last updated on 2/23/2024 by MarketBeat.com Staff